Skip to main content
Explore URMC

menu

Bladder Cancer: study on a drug delivery system (TAR-200)

Research Question:
Is TAR-200, an investigational drug delivery system, in combination with nivolumab safe and tolerable in patients with muscle-invasive bladder cancer (MIBC)?

Basic Study Information

Purpose:
TAR-200 is a drug-device product that continuously releases a chemotherapy drug (called gemcitabine) in the bladder over several days. The purpose of this study is to determine if TAR-200, when combined with a first-line treatment (a drug called nivolumab) is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC).

Location: University of Rochester Medical Center
Study Reference #: IGUB18046

Lead Researcher (Principal Investigator)

Lead Researcher: Chunkit Fung

Study Contact Information

Study Coordinator: Park Bogan
Phone: (585) 276-4415
Email: Park_Bogan@URMC.Rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search